{"denoms":[{"counts":[{"groupId":"BG000","value":"47"},{"groupId":"BG001","value":"84"},{"groupId":"BG002","value":"131"}],"units":"Participants"}],"groups":[{"description":"Participants received at least one protocol prescribed dose or higher of Romidepsin intravenously at 14mg/m\\^2 and at 17.5 mg/m\\^2 on days 1, 8, and 15 of a 28 day cycle.","id":"BG000","title":"Peripheral T-cell Lymphoma (PTCL)"},{"description":"Participants received at least one protocol prescribed dose or higher of Romidepsin intravenously at 14mg/m\\^2 and at 17.5 mg/m\\^2 on days 1, 8, and 15 of a 28 day cycle.","id":"BG001","title":"Cutaneous T-cell Lymphoma (CTCL)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"88"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"43"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"12.56","value":"58.97"},{"groupId":"BG001","spread":"13.08","value":"57.85"},{"groupId":"BG002","spread":"12.86","value":"58.25"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"49"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"82"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"5"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"46"},{"groupId":"BG001","value":"80"},{"groupId":"BG002","value":"126"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"21"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"65"},{"groupId":"BG002","value":"105"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"39"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"94"}]}],"title":"United States"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"37"}]}],"title":"Australia"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}],"populationDescription":"Although 7 cohorts were written in the protocol, the cohorts were consolidated for submission to the Food and Drug Administration (FDA) into the peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) groups, thus they are presented in this format."}